Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 7/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.41 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.41 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | MMP3 | P08254 | 2/20 | 0.38 |
| ▸ | MMP7 | P09237 | 2/20 | 0.38 |
| ▸ | MMP9 | P14780 | 2/20 | 0.38 |
| ▸ | MMP13 | P45452 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31155717 | 0.83 | CCR6 (0.58) | CCR6DRD2KDM4DKCNA3CTSK | |
| SCHEMBL29850045 | 0.82 | MAOB (0.46) | DRD2KAT6AKAT5KDM1AMAOB | |
| SCHEMBL30939416 | 0.82 | MAOB (0.46) | DRD2KAT6AKAT5KDM1AMAOB | |
| SCHEMBL6153963 | 0.78 | DRD2 (0.54) | CCR6DRD2KDM4DKDM1AMAOB | |
| SCHEMBL6153965 | 0.78 | DRD2 (0.54) | CCR6DRD2KDM4DKDM1AMAOB | |
| SCHEMBL29850181 | 0.78 | CCR6 (0.60) | CCR6KDM4DKAT6AKAT5 | |
| SCHEMBL30939380 | 0.77 | NAMPT (0.55) | — | |
| SCHEMBL32670457 | 0.77 | NAMPT (0.55) | — | |
| SCHEMBL5202966 | 0.76 | CTSK (0.53) | DRD2KDM4DGPR119KCNA3CTSK | |
| SCHEMBL1867760 | 0.75 | TGM2 (0.51) | KDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661964-A1 | COMPOUNDS AS CCR6 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-12-17 | — | — | EP | disclosed |
| US-20250353859-A1 | COMPOUNDS AS CCR6 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2025-11-20 | — | — | US | disclosed |
| WO-2024165453-A1 | COMPOUNDS AS CCR6 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353859-A1 | COMPOUNDS AS CCR6 INHIBITORS | CCR6, CCR4, CCR1 | CCR6 1/4885DRD2 1294/4885KDM4D 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.